Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The investigators wish to understand how resistance to malaria develops and how this affects the growth rate of malaria in individuals who have past exposure to malaria.
Full description
Malaria remains a major public health threat despite regulatory approval of a partially effective pre-erythrocytic malaria vaccine. There is an urgent need to accelerate the development of a more effective multi-stage vaccine. Controlled human malaria infection (CHMI) has been shown to be an important tool for the assessment of the efficacy of novel malaria vaccines and drugs prior to field trials. CHMI also allows for the evaluation of immunity to malaria and parasite growth rates in vivo. This is particularly useful in individuals from endemic areas with a level of exposure and immunity to malaria. Thus CHMI in individuals with prior exposure to malaria could be a valuable tool to accelerate malaria vaccine development. In this study, the investigators aim to use CHMI in semi-immune adults to provide a comprehensive prioritization of antigens associated with blood-stage immunity for vaccine development. The investigators will comprehensively characterize immunity to malaria using >100 antigens in up to 2,000 semi-immune adults, from known areas of malaria endemicity in Kenya, then select 200 individuals with a range of different immunological profiles, and conduct CHMI studies with serial quantitative polymerase chain reaction (PCR) to measure the parasite growth rate in vivo and relate this to host immunity. This will also involve analysing the relationship with functional immunity assessed by laboratory assays.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exclusion Criterion on Day of Challenge:
• Acute disease, defined as moderate or severe illness with or without fever (temperature >37.5°C).
Primary purpose
Allocation
Interventional model
Masking
200 participants in 1 patient group
Loading...
Central trial contact
Patricia Njuguna, MMed, MSc; Melissa Kapulu, DPhil
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal